教科书新辅助体验:为接受新辅助治疗的胰腺癌患者定义一种新型复合结果措施
Patrick W Underwood1, Thomas Leuschner1, Aslam Ejaz2
1From the Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH (Underwood, Leuschner, Dillhoff, Tsai, Pawlik, Cloyd).
Journal of the American College of Surgeons
|January 13, 2025
概括
在接受新辅助疗法 (NT) 的胰腺癌患者中,很少获得教科书中的新辅助体验 (TNE). 获得TNE显著改善整体存活率,突出其对治疗成功的重要性.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 新辅助疗法 (NT) 越来越多地用于胰腺管道腺癌 (PDAC).
- 在NT的挑战包括疾病的进展,毒性,和未能完成手术切除.
- 优化NT交付和结果需要强大的指标.
研究的目的:
- 定义和验证一个新的复合结果指标,以在PDAC中成功提供NT.
- 评估实现"教科书新辅助体验" (TNE) 的频率.
- 评估TNE与患者生存结果之间的关联.
主要方法:
- 对306名接受NT (2018-2023) 的局部PDAC患者的回顾性评估.
- 经过长期治疗的定义:在NT期间没有死亡率,疾病进展或住院治疗,加上完成NT和成功切除.
- 多变量考克斯回归分析以确定整体存活率的预测因素.
主要成果:
- 只有28%的患者获得了TNE.
- 潜在切除 (47%) 的TNE比边缘切除 (29%) 或局部发达 (7%) 的PDAC更常见.
- 患有TNE的患者的整体存活时间明显更长 (未达到与16.4个月相比,p < 0.001).
- 经过TNE是改善整体存活率的最强预测因素 (HR 0.33,p < 0.001).
结论:
- 在接受新辅助治疗的PDAC患者中,很少获得教科书中的新辅助体验 (TNE).
- 经期性脑脊髓炎与改善的长期存活率密切相关.
- 这种复合指标应纳入未来的研究,以更好地反映治疗成功,并指导PDAC中NT的优化策略.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.